November 9, 2009
Clinipace Acquires Worldwide Clinical Research, Inc. – Company Expands to Enhance its Global Clinical Operations Capabilities and Therapeutic Practice Areas
Morrisville, NC – Clinipace, global technology-driven clinical research organization (CRO), announced today that is has closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide, Inc.
October 8, 2009
Hatteras Announces Significant Realizations in HVP II – Trade Sales of B.R.A.H.M.S. and ESBATech Result in Full Return of Paid-in Capital to Limited Partners
RTP, NC – Hatteras Venture Partners announced today that the recent sales of B.R.A.H.M.S. Holdings GmbH to Thermo Fisher Scientific for $470 million and ESBATech AG to Alcon, Inc. for $150 million upfront plus $439 million in clinical milestone payments has resulted in a full return of paid-in capital for Hatteras Venture Partners II, LP (HVP II, formerly Hatteras BioCapital Fund, LP). With this return of capital and the remaining thirteen investments in the fund, HVP II is one of the best performing venture capital funds in its class, as compared to the benchmarks for 2004 venture capital funds.
August 31, 2009
Creating A Medical Device On The (Relatively) Cheap
WSJ.com – Capital efficiency is key for venture-backed start-ups, especially those health care companies engaging in costly clinical trials. SpineAlign Medical Inc., which has launched a medical device in Europe on just $13.6 million, shows that a lot can be done with relatively little capital. SpineAlign, which is developing a treatment for vertebral-compression fractures that commonly occur in osteoporosis patients, has kept outlays low by minimizing fixed costs, contracting out many services and keeping headcount low.
August 14, 2009
Embrella Cardiovascular, Inc. Announces Final Closing of Series B Round
Wayne, PA – Embrella Cardiovascular, Inc., a private company developing the next generation of embolic order tramadol online overnight shipping protection devices for use during coronary procedures, today announced the final closing of its Series B financing round, raising a total of $6.7 million in new capital.
July 23, 2009
SpineAlign Medical Treats First Patient in U.S. with New, Innovative System for Vertebral Compression Fracture Repair
San Jose, CA – SpineAlign Medical, Inc. (formerly SpineWorks Medical, Inc.) announced today the successful treatment of the first patient in its FDA Investigational Device Exemption (IDE) feasibility study. The SpineAlign System is designed for the treatment of vertebral compression fractures and features an innovative nitinol implant designed to achieve vertebral body reconstruction via a transpedicular, minimally-invasive approach.
July 7, 2009
Viamet Pharmaceuticals Secures $18M Financing
Research Triangle Park, NC – Viamet Pharmaceuticals, Inc. announced today that it has secured $18 million in a Series B financing to accelerate the development of its novel metalloenzyme inhibitors and to advance its Metallophile™ Technology platform. The proprietary Metallophile™ Technology is based on Viamet’s world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to rapidly and cost-effectively generate “best-in-class”, novel compounds by optimizing the metal-binding component of existing metalloenzyme inhibitors. The investment was led by the Novartis Option Fund and Lilly Ventures and also included Viamet’s existing investors Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund, and Astellas Venture Management. As part of the closing of the financing, Lauren Silverman, Ph.D., Managing Director of the Novartis Option Fund and Ed Torres, Managing Director, Lilly Ventures, have joined Viamet’s board of directors.
March 11, 2009
Pathfinder Hires Medical Device Veteran as CEO
Nashville, TN – Pathfinder, a medical device company with first to market products for “Surgical GPS” of the abdomen, announced that it has hired Skip Goode as President and CEO effective immediately. As head of Sales for leading edge companies including Medtronic Surgical Navigation, Accuray, and EndoGastric Solutions, Mr. Goode played a pioneering role in key product launches and sales efforts for innovative capital equipment and disposable tools in the surgical oncology field. Mr. Goode takes the helm in advance of the AHPBA conference where Pathfinder will launch its two FDA-cleared products for pre-operative planning and intra-operative navigation of liver surgery.